232 related articles for article (PubMed ID: 16034631)
21. Severe acneiform eruption induced by cetuximab (Erbitux).
Lee JE; Lee SJ; Lee HJ; Lee JH; Lee KH
Yonsei Med J; 2008 Oct; 49(5):851-2. PubMed ID: 18972607
[TBL] [Abstract][Full Text] [Related]
22. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Patel DK
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
[TBL] [Abstract][Full Text] [Related]
23. Panitumumab (Vectibix) for metastatic colorectal cancer.
Med Lett Drugs Ther; 2007 Apr; 49(1259):35-6. PubMed ID: 17450113
[No Abstract] [Full Text] [Related]
24. Severe acneiform rash.
Yamamoto DS; Viale PH; Zhao G
Clin J Oncol Nurs; 2004 Dec; 8(6):654-6. PubMed ID: 15637959
[No Abstract] [Full Text] [Related]
25. Eye complications of cetuximab therapy.
Melichar B; Nemcová I
Eur J Cancer Care (Engl); 2007 Sep; 16(5):439-43. PubMed ID: 17760931
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab-induced crusted pustular eruption with patchy alopecia.
Fischer R; Blackmon J; Rajpara A
Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526010
[TBL] [Abstract][Full Text] [Related]
27. [Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer].
Rodríguez-Murphy E; Villanueva-Herraiz S; Ortega-García MP; Pérez-Feliu A; López-Montenegro Soria MA; Camps-Herrero C
Farm Hosp; 2011; 35(3):114-20. PubMed ID: 21497124
[TBL] [Abstract][Full Text] [Related]
28. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
29. Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials.
Bauer KA; Hammerman S; Rapoport B; Lacouture ME
Clin Colorectal Cancer; 2008 Sep; 7(5):309-14. PubMed ID: 18794062
[TBL] [Abstract][Full Text] [Related]
30. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
[No Abstract] [Full Text] [Related]
31. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
[TBL] [Abstract][Full Text] [Related]
32. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
33. [Cutaneous side effects of EGF-receptor inhibition and their management].
Gutzmer R; Werfel T; Kapp A; Elsner J
Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
[TBL] [Abstract][Full Text] [Related]
34. The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience.
Giuliani J; Indelli M; Marzola M; Raisi E; Frassoldati A
Tumori; 2012; 98(4):408-12. PubMed ID: 23052154
[TBL] [Abstract][Full Text] [Related]
35. [Predictive factors of response to anti-EGFR treatments in colorectal cancer].
Lièvre A; Laurent-Puig P
Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579
[TBL] [Abstract][Full Text] [Related]
36. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors.
Kimyai-Asadi A; Jih MH
Arch Dermatol; 2002 Jan; 138(1):129-31. PubMed ID: 11790188
[No Abstract] [Full Text] [Related]
37. Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.
Duffour J; Thézenas S; Dereure O; Garcin A; Caron J; Samalin E; Portales F; Fiess C; Chalbos P; Gestin-Boyer C; Ychou M; Guillot B
Eur J Cancer; 2010 Dec; 46(18):3169-74. PubMed ID: 20417092
[TBL] [Abstract][Full Text] [Related]
38. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
Fakih M
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
[TBL] [Abstract][Full Text] [Related]
39. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
You B; Chen EX
J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
[TBL] [Abstract][Full Text] [Related]
40. Anti-EGFR monoclonal antibody-induced hypomagnesaemia.
Fakih M
Lancet Oncol; 2007 May; 8(5):366-7. PubMed ID: 17466890
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]